QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.108.141796v1 327/2/538    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Snider, N. T. Articles by Hollenberg, P. F. Search for Related Content PubMed PubMed Citation Articles by Snider, N. T. Articles by Hollenberg, P. F.

METABOLISM, TRANSPORT, AND PHARMACOGENOMICS

The Endocannabinoid Anandamide Is a Substrate for the Human Polymorphic Cytochrome P450 2D6

Department of Pharmacology, University of Michigan Medical School, Ann Arbor, Michigan (N.T.S., M.J.S., C.S., J.M.R., P.F.H.); and Section of Clinical Neuropharmacology, Neurosurgery University Hospital, Freiburg, Germany (T.J.F.)

Members of the cytochrome P450 (P450) family of drug-metabolizing enzymes are present in the human brain, and they may have important roles in the oxidation of endogenous substrates. The polymorphic CYP2D6 is one of the major brain P450 isoforms and has been implicated in neurodegeneration, psychosis, schizophrenia, and personality traits. The objective of this study was to determine whether the endocannabinoid arachidonoylethanolamide (anandamide) is a substrate for CYP2D6. Anandamide is the endogenous ligand to the cannabinoid receptor CB1, which is also activated by the main psychoactive component in marijuana. Signaling via the CB1 receptor alters sensory and motor function, cognition, and emotion. Recombinant CYP2D6 converted anandamide to 20-hydroxyeicosatetraenoic acid ethanolamide and 5,6-, 8,9-, 11,12-, and 14,15-epoxyeicosatrienoic acid ethanolamides (EET-EAs) with low micromolar K_m values. CYP2D6 further metabolized the epoxides of anandamide to form novel dioxygenated derivatives. Human brain microsomal and mitochondrial preparations metabolized anandamide to form hydroxylated and epoxygenated products, respectively. An inhibitory antibody against CYP2D6 significantly decreased the mitochondrial formation of the EET-EAs. To our knowledge, anandamide and its epoxides are the first eicosanoid-like molecules to be identified as CYP2D6 substrates. Our study suggests that anandamide may be a physiological substrate for brain mitochondrial CYP2D6, implicating this polymorphic enzyme as a potential component of the endocannabinoid system in the brain. This study also offers support to the hypothesis that neuropsychiatric phenotype differences among individuals with genetic variations in CYP2D6 could be ascribable to interactions of this enzyme with endogenous substrates.

Address correspondence to: Dr. Paul F. Hollenberg, Department of Pharmacology, University of Michigan, 2301 MSRB III, 1150 West Medical Center Dr., Ann Arbor, MI 48109-5632. E-mail: phollen{at}umich.edu

This article has been cited by other articles:

				F. Dutheil, S. Dauchy, M. Diry, V. Sazdovitch, O. Cloarec, L. Mellottee, I. Bieche, M. Ingelman-Sundberg, J.-P. Flinois, I. de Waziers, et al. Xenobiotic-Metabolizing Enzymes and Transporters in the Normal Human Brain: Regional and Cellular Mapping as a Basis for Putative Roles in Cerebral Function Drug Metab. Dispos., July 1, 2009; 37(7): 1528 - 1538. [Abstract] [Full Text] [PDF]

				N. T. Snider, J. A. Nast, L. A. Tesmer, and P. F. Hollenberg A Cytochrome P450-Derived Epoxygenated Metabolite of Anandamide Is a Potent Cannabinoid Receptor 2-Selective Agonist Mol. Pharmacol., April 1, 2009; 75(4): 965 - 972. [Abstract] [Full Text] [PDF]

				W.-Y. Zhang, Y.-B. Tu, R. L. Haining, and A.-M. Yu Expression and Functional Analysis of CYP2D6.24, CYP2D6.26, CYP2D6.27, and CYP2D7 Isozymes Drug Metab. Dispos., January 1, 2009; 37(1): 1 - 4. [Abstract] [Full Text] [PDF]